Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer
The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product DRibble Platform Vaccine 001(DPV-001) in combination with BMS’ anti-OX40 (BMS-986178) combined with sequenced administration